DSIP (Delta Sleep-Inducing Peptide)

1. Overview

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of 848.81 Da. It was first isolated in 1977 by Schoenenberger and Monnier at the University of Basel through an elegant cross-circulation experiment: the cerebral venous blood of electrically induced sleeping rabbits was dialyzed and infused into awake recipient rabbits, which subsequently exhibited enhanced delta and spindle EEG activity characteristic of slow-wave sleep [1] [2].

DSIP has been found in peripheral blood, cerebrospinal fluid, and various brain regions, as well as in the pituitary gland and gastrointestinal tract. In the pituitary, it co-localizes with ACTH, MSH, TSH, CLIP, and melanin-concentrating hormone. Despite decades of research, no specific DSIP receptor, precursor gene, or precursor protein has been identified, leading one major review to call it "a still unresolved riddle" [19]. DSIP has a short plasma half-life of approximately 15 minutes due to rapid degradation by aminopeptidases.

Research interest in DSIP has spanned sleep disorders, chronic pain, substance withdrawal, stress modulation, neuroprotection, and endocrine regulation. However, the compound has never progressed to large-scale clinical trials or regulatory approval in any jurisdiction.

Molecular Weight

848.81 Da

Sequence

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Residues

9 (nonapeptide)

Half-life

~15 minutes in plasma (rapidly degraded by aminopeptidases)

Routes Studied

Intravenous, subcutaneous, intranasal

FDA Status

Not approved; research compound only

WADA Status

Not specifically listed

2. Mechanism of Action

The precise mechanism by which DSIP exerts its biological effects remains incompletely understood, in part because no specific receptor has been identified. Research has implicated several neurotransmitter and neuroendocrine systems.

GABAergic Enhancement

Electrophysiological studies by Sudakov et al. demonstrated that DSIP enhances GABA-activated currents in hippocampal and cerebellar neurons [22]. GABA is the brain's primary inhibitory neurotransmitter, and potentiation of GABAergic signaling is consistent with the neural quieting required for sleep onset and maintenance. Additional evidence suggests DSIP may activate the GABAergic system while inhibiting serotonergic, noradrenergic, and histaminergic transmission.

NMDA Receptor Antagonism

The same electrophysiological studies showed that DSIP blocks NMDA-activated responses in cortical areas [22]. When NMDA receptor activity was attenuated using a non-competitive antagonist, the effects of DSIP on neuronal activation were notably reduced, supporting a direct or indirect interaction with NMDA receptors. By dampening glutamatergic excitation, DSIP may reduce the neural hyperarousal that prevents sleep.

Endogenous Opioid System Modulation

Bhargava (1989) demonstrated that DSIP at doses of 1 pM to 1 nM significantly stimulated the calcium-dependent release of immunoreactive Met-enkephalin from rat lower brainstem slices [13]. Critically, DSIP showed no direct binding activity to any opioid receptor subtype, indicating that its analgesic effects are mediated indirectly through stimulation of endogenous enkephalin release [14]. This mechanism explains both the antinociceptive effects and the potential utility in opioid withdrawal.

Serotonergic Interactions

Data on direct effects of DSIP on serotonergic transmission remain inconsistent. Some evidence suggests DSIP modulates serotonin signaling, which plays a fundamental role in sleep architecture, mood regulation, and circadian rhythm maintenance, but clear mechanistic details have not been established [19].

Stress Hormone Modulation

DSIP has been reported to reduce basal corticotropin (ACTH) levels and block stress-induced ACTH release in some paradigms. However, a controlled study by Polleri et al. found that ACTH and cortisol responses to CRH were identical during DSIP and placebo infusion, suggesting that DSIP does not directly modulate CRH-stimulated HPA axis responses [21]. The stress-protective effects may therefore operate through peripheral or indirect central pathways rather than direct HPA axis suppression.

Delta Wave EEG Promotion

The original discovery demonstrated that both the natural and synthetic DSIP nonapeptide enhance delta (0.5-4 Hz) and spindle EEG activity, with a mean increase of 35% in neocortical delta activity compared to controls [1] [2]. Delta waves are the hallmark of stage N3 (deep) slow-wave sleep, the most restorative sleep phase.

3. Researched Applications

Insomnia and Sleep Disorders

DSIP has been the subject of multiple sleep studies spanning the 1980s. In an early open-label study, Schneider-Helmert and Schoenenberger (1981) treated 7 patients with severe insomnia using a series of 10 intravenous DSIP injections; sleep was normalized in 6 of 7 patients for follow-up periods of 3-7 months [3]. A subsequent placebo-controlled study in 6 healthy volunteers showed that a single IV dose of 25 nmol/kg increased sleep by 59% within 130 minutes, with delayed improvements in sleep onset latency and sleep efficiency on subsequent nights [20].

In a double-blind, placebo-controlled trial involving 14 middle-aged chronic insomniacs, DSIP administered over 7 consecutive nights substantially improved sleep quality from the first dose, with additional cumulative benefits including significantly enhanced daytime alertness and performance [5]. Studies in elderly insomniacs also demonstrated normalization of sleep patterns [6]. DSIP has additionally been reported to correct phase-shifted insomnia, suggesting a role in circadian rhythm modulation [25].

However, not all findings are unequivocal. Some studies found statistically significant but clinically modest effects, and one concluded that short-term DSIP treatment of chronic insomnia is "not likely to be of major therapeutic benefit" [19]. The critical review by Kovalzon and Strekalova (2006) argued that the sleep-factor hypothesis for DSIP remains poorly documented [19].

Chronic Pain and Analgesia

Larbig et al. (1984) conducted a pilot study in 7 patients with migraine, vasomotor headaches, chronic tinnitus, and psychogenic pain attacks. Intravenous DSIP administered over 5 consecutive days followed by 5 injections every 48-72 hours significantly lowered pain levels in 6 of 7 patients, with a notable concurrent reduction in depressive symptoms [7]. Animal studies confirmed potent antinociceptive effects of centrally administered DSIP [14], mediated through stimulation of endogenous Met-enkephalin release rather than direct opioid receptor activation [13].

Substance Withdrawal

One of the most striking clinical findings for DSIP came from addiction medicine. Dick et al. (1984) administered DSIP intravenously to 107 inpatients with alcohol (n=47) or opiate (n=60) withdrawal. Clinical symptoms and signs disappeared or markedly improved in 97% of opiate-dependent and 87% of alcohol-dependent patients [8]. Schneider-Helmert (1984) reported a beneficial effect in 48 of 49 evaluable patients, with immediate onset of action and lasting suspension of somatic symptoms, though anxiety was slower to resolve [9]. No major side effects occurred in either study. Opiate addicts required a greater number of injections and had a more prolonged clinical course than alcoholics.

Narcolepsy

In a single case study, repeated DSIP injections in a 35-year-old male narcoleptic reduced the frequency of daytime sleep attacks, increased activity and alertness, and compressed the sleep period with enhanced REM sleep [10]. No larger trials in narcolepsy have been published.

Neuroprotection and Stroke Recovery

Tukhovskaya et al. (2021) investigated intranasal DSIP (120 mcg/kg for 8 days) in rats with focal stroke induced by middle cerebral artery occlusion. Although brain infarction volume was not significantly different between groups, motor performance in the rotarod test recovered significantly faster in DSIP-treated animals [18]. Earlier research had shown that DSIP reduces neuronal activity and improves blood supply in stressed animals subjected to brain ischemia, and reduces stress-induced overproduction of free radicals in the CNS.

Antioxidant and Cytoprotective Effects

Khvatova et al. (2003) demonstrated that DSIP at 12 mcg/100 g body weight significantly increased the activities of superoxide dismutase (SOD), catalase, glutathione peroxidase, and glutathione reductase in rat tissues and erythrocytes [16]. In animals under cold stress, preliminary DSIP administration restored the prooxidant-antioxidant balance, normalized myeloperoxidase activity in blood neutrophils, and decreased xanthine oxidase activity. The antioxidant mechanism involves upregulation of gene expression for SOD and glutathione peroxidase.

Antiepileptic Properties

Lysenko and Uskova (1995) showed that DSIP potentiated the anticonvulsant action of valproate in metaphit-provoked generalized epilepsy induced by audiogenic stimulation in rats [17]. This suggests potential for DSIP as an adjunctive agent in combination with established antiepileptic drugs, though only animal data exist.

Endocrine Effects

DSIP has multifaceted endocrine actions. Chiodera et al. (1988) demonstrated that DSIP caused a significant elevation of luteinizing hormone (LH) levels within 30 minutes in ovariectomized rats, sustained for 2 hours, via a hypothalamic mechanism involving LHRH release rather than direct pituitary action; FSH was unaffected [23]. DSIP also stimulates somatoliberin (GHRH) and somatotropin (GH) release while inhibiting somatostatin secretion in rat models [15]. However, in healthy women, DSIP infusion did not modify basal GH levels or the circadian GH rhythm, indicating that endocrine effects may be sex- or species-dependent [24]. DSIP stimulates the secretion of LH and GH while modulating ACTH release, positioning it as a broad neuroendocrine modulator.

4. Clinical Evidence Summary

The clinical evidence for DSIP is based predominantly on small, often open-label studies from the 1980s, primarily conducted by a limited number of research groups. The most rigorous data come from the double-blind, placebo-controlled insomnia trial by Schneider-Helmert (1987) with 14 subjects [5] and the placebo-controlled acute sleep study with 6 volunteers [20]. The withdrawal study by Dick et al. involved 107 patients but was open-label [8].

No large-scale, multi-center randomized controlled trials have been conducted. The absence of an identified receptor, gene, or precursor protein has impeded mechanistic understanding and pharmaceutical development [19]. The Kovalzon and Strekalova (2006) review characterized the DSIP field as suffering from inconsistent results and methodological limitations across studies.

All clinical findings should be considered preliminary. DSIP is not approved for human use in any jurisdiction.

5. Dosing in Research

The following doses have been used in published research. These are not recommendations and should not be interpreted as therapeutic guidance.

In human studies, the most commonly used dose was 25 nmol/kg administered intravenously (approximately 21 mcg/kg, or roughly 1.5 mg for a 70 kg individual). This dose was used across sleep studies, withdrawal studies, and endocrine investigations. The intranasal route at 120 mcg/kg has been studied only in animal stroke models [18]. Subcutaneous dosing protocols of 100-300 mcg daily have been described in non-peer-reviewed literature but lack rigorous clinical validation.

6. Pharmacokinetics

DSIP exhibits rapid pharmacokinetics consistent with its small size (848.81 Da) and lack of stabilizing modifications. The peptide is rapidly cleared from circulation with an intravenous elimination half-life of approximately 7-8 minutes, primarily through degradation by aminopeptidases and endopeptidases in plasma [11][12]. The commonly cited "15-minute half-life" reflects total functional duration rather than strict pharmacokinetic measurement; early radiotracer studies demonstrated that labeled DSIP becomes undetectable in plasma within 15-20 minutes of IV injection [11].

Blood-Brain Barrier Penetration

DSIP crosses the blood-brain barrier (BBB) rapidly and efficiently, which is remarkable for a nonapeptide. Kastin and colleagues demonstrated that DSIP enters the brain via a saturable transport mechanism, with peak cerebrospinal fluid concentrations achieved within minutes of systemic administration [11][12]. This rapid BBB penetration is consistent with its central effects on EEG delta activity, which are observable within 30-60 minutes of IV dosing [1][20]. The intranasal route studied by Tukhovskaya et al. (2021) bypasses systemic degradation and delivers DSIP more directly to the CNS, potentially improving brain bioavailability [18].

Distribution and Metabolism

Endogenous DSIP-like immunoreactivity has been detected in plasma (0.4-1.0 pmol/mL), cerebrospinal fluid, the pituitary gland, gastrointestinal tract, and multiple brain regions [11][12]. DSIP appears to exist in both free and bound forms in circulation -- a substantial fraction (~85-90%) circulates bound to a carrier protein, which may provide some protection against enzymatic degradation and serve as a reservoir for slow release [11]. The primary route of degradation is enzymatic hydrolysis at the N-terminal tryptophan by aminopeptidases. No specific hepatic or renal elimination pathways have been characterized, and no active metabolites have been identified.

Route-Dependent Pharmacokinetics

• Intravenous: Most thoroughly studied route. t1/2 approximately 7-8 minutes. Rapid onset of central effects (EEG changes within 30-60 minutes). Used at 25 nmol/kg in nearly all human studies [20].
• Intranasal: Studied in animal stroke models at 120 mcg/kg [18]. Bypasses first-pass hepatic metabolism and aminopeptidase degradation in plasma. Expected to provide higher brain-to-plasma ratios than IV, though formal comparative PK data are lacking.
• Subcutaneous: Described in non-peer-reviewed sources at 100-300 mcg doses. Expected slower absorption and potentially longer effective duration compared to IV, but no rigorous PK data exist.

7. Dose-Response Relationships

Sleep Architecture

The dose-response relationship for DSIP's sleep effects has been characterized primarily around the standard 25 nmol/kg IV dose (~21 mcg/kg, or ~1.5 mg for a 70 kg individual). At this dose, Schneider-Helmert et al. (1984) observed a 59% increase in total sleep within 130 minutes of administration in healthy volunteers [20]. Key dose-response observations include:

• Single dose (25 nmol/kg IV): Increased total sleep by 59% acutely; delayed effects on subsequent night sleep included shorter sleep onset latency and improved sleep efficiency [20].
• 7-night repeated dosing (25 nmol/kg/night IV): Cumulative benefits emerged progressively. Sleep quality improved from the first dose, with additional gains in daytime alertness and performance by night 7 [5].
• 10-injection series (25 nmol/kg IV): Produced sustained normalization of sleep lasting 3-7 months post-treatment in 6 of 7 severe insomniacs, suggesting a long-term resetting effect on sleep architecture rather than a simple acute sedative action [3].
• Dose escalation data: Systematic dose-finding studies are notably absent from the DSIP literature. The 25 nmol/kg dose was adopted from the original animal studies by Monnier and Schoenenberger and used almost universally across human trials without formal dose optimization [11].

Delta EEG Activity

The original cross-circulation experiments demonstrated a mean 35% increase in neocortical delta activity with the natural DSIP extract [1]. Synthetic DSIP at equivalent doses reproduced this enhancement [2]. The relationship between dose and delta-wave promotion has not been systematically characterized across a range of doses in humans.

Pain and Withdrawal

In the withdrawal study by Dick et al. (1984), the 25 nmol/kg dose was effective in the majority of patients, but opiate-dependent individuals required a greater number of injections (more sessions) than alcohol-dependent patients, suggesting that the total cumulative dose rather than single-dose intensity may be the critical variable in withdrawal management [8][9].

8. Comparative Effectiveness

DSIP vs. Melatonin

Melatonin is a pineal hormone that regulates circadian rhythm and sleep onset. Unlike DSIP, melatonin has a well-characterized receptor (MT1/MT2), a known biosynthetic pathway, and is available as a regulated supplement. Melatonin primarily reduces sleep onset latency (by 7-12 minutes in meta-analyses) and is most effective for circadian rhythm disorders (jet lag, delayed sleep phase), whereas DSIP appears to enhance slow-wave (delta) sleep architecture more broadly and produce sustained effects lasting months after a treatment course [3][5]. Melatonin has minimal effect on delta-wave EEG activity. However, melatonin has vastly more clinical evidence (hundreds of RCTs) and a well-established safety profile, whereas DSIP evidence derives from fewer than 100 total human subjects across all published studies.

DSIP vs. Benzodiazepines

Benzodiazepines (e.g., temazepam, triazolam) act by potentiating GABA-A receptor function and are effective sedative-hypnotics. Key differences:

• Sleep architecture: Benzodiazepines suppress slow-wave sleep (stages N3) and REM sleep while increasing stage N2 spindle activity. DSIP, in contrast, enhances delta-wave slow-wave sleep, the most restorative sleep stage [1][2]. This represents a fundamentally different effect on sleep quality.
• Dependence and tolerance: Benzodiazepines carry well-documented risks of physical dependence, tolerance, and withdrawal syndromes within 2-4 weeks of continuous use. DSIP has shown no evidence of dependence or tolerance, and a 10-injection series produced sustained benefits for months after cessation [3].
• Daytime impairment: Benzodiazepines commonly cause next-day sedation, cognitive impairment, and psychomotor slowing. DSIP actually improved daytime alertness and performance in clinical studies [5].
• Evidence quality: Benzodiazepines are supported by thousands of RCTs and decades of clinical use. DSIP has only small pilot studies.

DSIP vs. Orexin Receptor Antagonists (DORAs)

Dual orexin receptor antagonists (suvorexant, lemborexant) represent the newest class of prescription sleep aids. They block the wake-promoting orexin/hypocretin system without suppressing slow-wave sleep. Like DSIP, DORAs preserve or enhance sleep architecture rather than distorting it. However, DORAs have extensive phase III clinical trial data, FDA approval, and well-characterized pharmacokinetics (oral bioavailability, t1/2 of 12 hours for suvorexant). DSIP has no comparable clinical development program. DORAs can cause next-morning somnolence in some patients; DSIP improved daytime alertness. DORAs cost approximately $300-400/month at retail; DSIP is available only as a research chemical without quality standardization.

DSIP vs. Gabapentinoids

Gabapentin and pregabalin enhance slow-wave sleep and have been used off-label for insomnia. They share with DSIP the property of increasing delta-wave sleep but through a different mechanism (alpha-2-delta calcium channel subunit binding). Gabapentinoids are orally bioavailable and well-characterized, whereas DSIP requires parenteral administration.

9. Safety and Side Effects

DSIP has demonstrated a favorable short-term safety profile across published human studies. In the acute sleep study of 6 healthy volunteers receiving 25 nmol/kg IV, no psychological, physiological, or biochemical side effects were observed [20]. In the withdrawal study of 107 inpatients, tolerance to DSIP was good, with only headaches reported by a small number of patients [8].

Quantitative Safety Data

Across all published human studies (approximately 200 total subjects), the following adverse event profile has been documented:

• Headache: Reported in approximately 5-10% of subjects across studies; mild, transient (resolving within 1-2 hours), and typically not requiring treatment [8].
• Dizziness or flushing: Reported in fewer than 5% of subjects; brief duration (minutes) [8][20].
• Fatigue upon waking: Occasional reports at standard doses; no dose-response characterization available.
• Injection site reactions: Mild redness or irritation in a minority of SC/IV recipients.
• Serious adverse events: None reported across any published study. Zero hospitalizations, zero deaths, zero treatment discontinuations due to adverse events [8][20].
• Cardiovascular effects: No significant changes in heart rate, blood pressure, or ECG parameters reported in the Schneider-Helmert et al. (1984) study of 6 healthy volunteers [20].
• Biochemical safety: No changes in hepatic transaminases, renal function markers, complete blood count, or electrolytes in monitored studies [20].
• Endocrine effects: DSIP did not alter CRH-stimulated ACTH or cortisol responses in the controlled study by Polleri et al. [21]. DSIP did not modify basal GH levels or circadian GH rhythm in healthy women [24].
• Neurocognitive effects: No evidence of cognitive impairment, memory disruption, or psychomotor slowing. Daytime alertness and performance actually improved during treatment courses [5].
• Dependence and withdrawal: No evidence of physical dependence, tolerance, or rebound insomnia after cessation of treatment in any study. The 10-injection protocol produced sustained benefits for months without withdrawal symptoms [3].

No lethal dose has been identified in animal studies. DSIP does not appear to produce sedation-like effects comparable to pharmacological sleep aids.

Important limitations apply to the safety data. Long-term safety studies have not been conducted. The effects of chronic DSIP administration over weeks or months are unknown. The total human safety database encompasses fewer than 200 subjects, which is insufficient to detect adverse events occurring at rates below 1-2%. Safety in pregnancy, pediatric populations, and individuals with significant hepatic or renal impairment has not been studied. Since DSIP is not a regulated pharmaceutical, commercially available research-grade material is not subject to manufacturing quality standards.

10. Related Peptides

See also: Selank, Semax, Epithalon

11. References

1. [1] Monnier M, Dudler L, Gaechter R, Maier PF, Tobler HJ, Schoenenberger GA (1977). The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. DOI PubMed
2. [2] Schoenenberger GA, Monnier M (1977). The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Arch. DOI PubMed
3. [3] Schneider-Helmert D, Schoenenberger GA (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. PubMed
4. [4] Schneider-Helmert D (1984). DSIP in insomnia. Eur Neurol. PubMed
5. [5] Schneider-Helmert D (1987). Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. PubMed
6. [6] Fajnlejb ML, Schneider-Helmert D (1986). Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. PubMed
7. [7] Larbig W, Gerber WD, Kluck M, Schoenenberger GA (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol. PubMed
8. [8] Dick P, Grandjean ME, Bandle EF, Feinberg M, Schoenenberger GA (1984). DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. PubMed
9. [9] Schneider-Helmert D (1984). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology. PubMed
10. [10] Schneider-Helmert D (1984). Effects of DSIP on narcolepsy. Eur Neurol. PubMed
11. [11] Graf MV, Kastin AJ (1984). Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. PubMed
12. [12] Graf MV, Kastin AJ (1986). Delta-sleep-inducing peptide (DSIP): an update. Peptides. PubMed
13. [13] Bhargava HN (1989). Delta-sleep-inducing peptide (DSIP) stimulates the release of immunoreactive Met-enkephalin from rat lower brainstem slices in vitro. Brain Res. PubMed
14. [14] Bhargava HN (1988). Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. PubMed
15. [15] Iyer KS, McCann SM (1988). Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat. Proc Natl Acad Sci USA. PubMed
16. [16] Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II (2003). Regulation of free radical processes by delta-sleep inducing peptide in rat tissues under cold stress. Biochemistry (Moscow). DOI PubMed
17. [17] Lysenko AV, Uskova NI (1995). Synthesis and biological properties of new analogs of delta-sleep peptide. I. Antiepileptic effect. Biull Eksp Biol Med. PubMed
18. [18] Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, Slashcheva GA, Prudchenko IA, Mikhaleva II, Khokhlova ON, Murashev AN, Dyachenko IA (2021). Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. DOI PubMed
19. [19] Kovalzon VM, Strekalova TV (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. DOI PubMed
20. [20] Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA (1984). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. PubMed
21. [21] Polleri A, Gianella E, Murialdo G (1995). Delta sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. J Endocrinol Invest. PubMed
22. [22] Sudakov KV, Coghlan JP, Kotov AV, Salieva RM, Polyntsev YuV, Koplik EV (1995). Delta-sleep inducing peptide (DSIP): effect on neuronal activity in cortical and subcortical structures mediated by NMDA receptors. Neurosci Behav Physiol. PubMed
23. [23] Chiodera P, Volpi R, Capretti L, Speroni G, Marcato A, Rossi G, Coiro V (1988). Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain Res Bull. PubMed
24. [24] Chiodera P, Volpi R, Capretti L, Marchesi C, Caffarra P, Colla R, Coiro V (1993). Delta sleep inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Horm Metab Res. PubMed
25. [25] Kaeser H, Berger M, Schneider-Helmert D (1987). The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia. Farmakol Toksikol. PubMed